In the context of future AAV-based clinical trials for Duchenne myopathy, AAV genome fate in dystrophic muscles is of importance considering the viral capsid immunogenicity that prohibits recurring treatments. We followed AAV genome copy numbers after AAV-U7 delivery in the mdx dystrophic mouse. We showed that AAV genomes encoding nontherapeutic U7 were lost from mdx muscles within three weeks after intra-muscular injection. In contrast, AAV genomes encoding U7ex23 restoring expression of a slightly shortened dystrophin were maintained endorsing that the arrest of the dystrophic process is crucial for maintaining viral genomes in transduced fibers. Indeed, muscles treated with low doses of AAV-U7ex23, resulting in sub-optimal exon-skipping, displayed much lower titers of viral genomes, showing that sub-optimal dystrophin restoration does not prevent AAV genome loss. We also followed therapeutic viral genomes in severe dystrophic dKO mice over time after systemic treatment with scAAV9-U7ex23. Dystrophin restoration decreased significantly between 3 and 12 months in various skeletal muscles, which was correlated with important viral genome loss, except in the heart. Altogether these data show that the success of future AAV-U7 therapy for Duchenne patients would require optimal doses of AAV-U7 to induce substantial levels of dystrophin to stabilize the treated fibers and maintain the long lasting effect of the treatment. The Sgcb-null mouse model, with beta-sarcoglycan knocked-down, develops severe muscular dystrophy with early fibrosis like the human limb girdle muscular dystrophy type 2E. The mdx mouse, lacking dystrophin, is the most used model for Duchenne muscular dystrophy (DMD). Unlike DMD, the mdx mouse has mild clinical features and shows little endomysial fibrosis in limb muscles. We have characterized the progression of muscle fibrosis, at molecular and histopathological level, in the Sgcb-null mouse and compared results to findings in the mdx. We evaluated expression of collagen I, III and VI, and of decorin and TGFbeta1 by immunohistochemistry or immunoblotting, and transcript levels by RealTime PCR, in the quadriceps and diaphragm muscles, at 2, 4, 8, 12, 26 and 52 weeks in the sgcb-null mouse, and at 12, 26 and 52 weeks in the mdx. We found severe histopathological features from 4 weeks on, and concomitant deposition of extracellular matrix components in the Sgcb-null mouse, with collagen I, III and VI significantly increased since early ages both in the quadriceps and diaphragm.
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When compared to the mdx muscles, histopatological features of both Sgcb-null and age-matched mdx mice were similar at all examined ages except that in Sgcb-null mice the extent of connective tissue was generally greater. This was particularly evident in the quadriceps muscle where the endomysial connective tissue was prominent and the extent of the various collagens was significantly greater in the Sgcb-null mice at all ages compared to mdx. Furthermore, differently than in the Scgb-null mouse, where the amount all of three collagen isoforms increased steadily, in the mdx they remained stable.
The Sgcb-null mouse represents a useful model for evaluating the pathogenetic mechanisms of muscle fibrosis and for development of anti-fibrotic treatments. The possibility to treat Duchenne dystrophy (DMD) through cell therapy has been widely investigated but before starting clinical trials in humans many questions still need to be addressed in pre-clinical studies. In addition to clarifying the role of the exogenous cells in dystrophic muscle, one important concern is whether there is an increased risk of tumors or any other long-term side effects following stem-cells injections. Since murine models have a short life span, the best animal model to address these questions is the Golden Retriever Muscular Dystrophy (GRMD) dog, which reproduces the full spectrum of human DMD. They present clinical signs within the first weeks of life and most of them do not survive beyond age two. However, due to their phenotype variability each dog must be compared separately before and after any experiment. We have injected human adipose-derived mesenchymal stromal cells (hAMSCs), from two different donors, in three GRMD dogs, without immunosuppression. They were injected in the cephalic vein with 5 Â 107 cells/kg within their first year of life: weekly in the first month of injections and then monthly. Dolar and Yuan were born in September of 2008 and Rum in July of 2011. In Dolar and Yuan, who received cells from donor 1, we observed that hAMSCs injected systemically were able to reach and express human dystrophin in the host GRMD dystrophic muscle up to 6 months after transplantation. When cells from donor 2 were injected in Rum, no human dystrophin was found in the host muscle. However, the three dogs showed clinical improvement following hAMSCS injections with an apparent stabilization afterwards, suggesting a beneficial effect from factors released by the injected cells. Most importantly, after almost four years of follow-up for Dolar and Yuan there was no tumor or other side effect suggesting that hAMSCS transplantation is a safe procedure, which may have important applications for future therapy in muscular dystrophy patients.
http://dx.doi:10.1016/j.nmd.2013.06.700 P.20.11 Dystrophin rescue needed to recover a correct location of nNOS and the return to a normalized RyR1 status in treated GRMD dogs C. The most promising gene therapy approaches to treat Duchenne Muscular Dystrophy (DMD) is currently the use of the exon skipping strategy as shown by clinical trials underway. However, truncated dystrophins resulting from exon skipping may be more or less efficacious depending on the effect of the truncation on the protein function. In particular, the neuronal nitric oxide synthase (nNOS) binding site to the dystrophin has been defined on the repeats 16 and 17 (R16/17). Considering that R16/17 are encoded by exons 42-45 of dystrophin mRNA, an alteration in this zone could impact on the integrity of the nNOS binding site preventing the proper binding of nNOS to dystrophin.
Several studies have provided convincing evidence that mis-localization of nNOS and cytosolic NO impair skeletal muscle contractibility via nitrosylative modification of the sarcoplasmic reticulum calciumrelease-channel RyR1. These data point towards nitrosylation-induced leakiness of the RyR1 as a molecular mechanism underlying muscle weakness and highlight that the dystrophin rescue has to take into account its functional properties such as nNOS binding.
Considering these facts, we have evaluated the level of dystrophin restoration needed to recover, qualitatively and quantitatively, a correct location of nNOS. For this study, we have collected biopsies from GRMD dogs (the DMD model) treated by exon skipping strategy and for whom muscles display a range from 5% to 95% of dystrophin positive fibers. The location and the activity of nNOS as well as the status of RyR1 nitrosylation have been investigated following the rank of dystrophin rescue. This study allowed to define the level of dystrophin restoration necessary for the proper nNOS localization and for the return to the normalization of the RyR1 status, two crucial parameters to be investigated in DMD therapy for which both, the dystrophin restoration and the muscular function rescue, are the goal.
